AVENUE THERAPEUTICS INC
For the period ended Dec 31, 2023. Filed Mar 18, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 18, 2024
ATXI$0.42-50.7%Stored close · as of Mar 18, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
(In thousands, except share and per share amounts)
| For the Years Ended | ||
|---|---|---|
| December 31, | December 31, | |
| 2023 | 2022 | |
| Operating expenses | ||
| Research and development | $6,131 | $2,698 |
| Research and development - licenses acquired | 4,230 | — |
| General and administrative | 4,179 | 5,345 |
| Loss from operations | (14,540) | (8,043) |
| Interest income | (126) | (20) |
| Financing costs – warrant liabilities | 332 | 1,160 |
| Change in fair value of warrant liabilities | (4,258) | (5,580) |
| Net loss | $(10,488) | $(3,603) |
| Net loss attributable to non-controlling interests | (111) | (51) |
| Net loss attributable to common stockholders | $(10,377) | $(3,552) |
| Net loss per common share attributable to common stockholders, basic and diluted | $(0.98) | $(1.63) |
| Weighted average number of common shares outstanding, basic and diluted | 10,591,636 | 2,185,159 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.